NAACCR Item #1174: PD-L1
| Item # | Length | Source of Standard | Section Name | Year Implemented | Version Implemented | XML NAACCR ID | Parent XML Element |
|---|---|---|---|---|---|---|---|
| 1174 | 5 | NAACCR | Stage/Prognostic Factors | 2025 | 25 | pdl1 | Tumor |
Required Status:
NPCR Collect: Required, site specific; when available
CoC Collect: Required, site specific
SEER Collect: Required, site specific
CCCR Collect: Required, site specific; when available
Description
The absence or presence of PD-L1 expression determines if the tumor will respond to treatment with a targeted inhibitor (immunotherapy). PD-L1 is done for Non-small cell lung cancers (NSCLC).
Rationale
PD-L1 is recommended by treatment guidelines for lung cancer to determine if the patient may benefit from checkpoint inhibitor drugs (immunotherapy). It is a new data item for cases diagnosed 1/1/2025+.
Allowable Values
0.0, 0.1-100.0, XXX.2, XXX.3, XXX.4, XXX.7, XXX.8, XXX.9
Codes
| Code | Description |
|---|---|
| 0.0 | No PD-L1 expression identified Tumor Proportion Score (TPS) = 0% |
| 0.1-100.0 | 0.1-100.0 PD-L1 expression Tumor Proportion Score (TPS) = 0.1%-100.0% |
| XXX.2 | PD-L1 expression absent AND Tumor Proportion Score (TPS) stated as negative |
| XXX.3 | PD-L1 expression present AND Tumor Proportion Score (TPS) stated as low |
| XXX.4 | PD-L1 expression present AND Tumor Proportion Score (TPS) stated as high/positive |
| XXX.7 | Test ordered, results not in chart |
| XXX.8 | Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error) |
| XXX.9 | Not documented in medical record No microscopic confirmation of tumor PD-L1 cannot be determined PD-L1 not assessed or unknown if assessed |
| Blank | NA - Diagnosis year is prior to 2025 |
Code Notes
**Note 1:** This SSDI is effective for diagnosis years 2025+.
* For cases diagnosed 2018-2024, leave this SSDI blank
**Note 2:** Physician statement PD-L1 can be used to code this data item when no other information is available.
**Note 3:** The absence or presence of PD-L1 expression determines if the tumor will respond to treatment with a targeted inhibitor. PDL-1 is done for Non-Small Cell lung cancers (NSCLC)
**Note 4:** If neoadjuvant therapy is given, record the assay from tumor specimens prior to neoadjuvant therapy.
* If neoadjuvant therapy is given and there are no PD-L1 results from pre-treatment specimens, report the findings from post-treatment specimens